Resistant Major Depression Clinical Trial
Official title:
Pilot Study of Feasibility of the Effect of Treatment With tDCS in Patients Suffering From Resistant Depression
The purpose of the study is to investigate the effect of tDCS applied at the anodic left DLPFC of patients with resistant depression compared to patients treated with conventional therapy. The tDCS is used in add-on drug treatment with antidepressants of reference in resistant depression.
The aim of our study is to investigate the effect of tDCS applied at the anodic left
dorsolateral prefrontal cortex (DLPFC)of patients with resistant depression compared to
patients treated with conventional therapy. The tDCS is used in add-on drug treatment with
antidepressants of reference in resistant depression.
This is a randomized 2-arm parallel, double blind study comparing 2 groups of 12 patients:
patients treated with sham tDCS and whose medication reference is stabilized for a month vs.
patients treated by active tDCS 10 sessions over five days and whose medication reference is
stabilized for a month. The 24 patients with resistant depression will be selected in the
psychiatric department of the University Hospital of Besançon. After giving informed
consent, patients will be evaluated by a psychiatrist using the Montgomery Asberg Depression
Rating Scale (MADRS), the Hamilton Depression Rating Scale (HDRS), State-Trait Anxiety
Inventory (STAI) and Beck Depression Inventory (BDI). The complete assessment takes 40
minutes.
After locating the left DLPFC, treatment with active tDCS with a current of 2 mA or sham
will be directed by 20-minute session. A psychometric assessment will be conducted again at
the end of treatment week and one month, three months and finally six months after stopping
treatment. Scales of comfort and acceptability will also be proposed to the patient to
determine whether any gene is caused by this treatment.
This study will include two parallel arms:
- a group named G1 and treated by medication with escitalopram (Seroplex®) stabilized for
at least 1 month and 10 sessions of tDCS anode active at 2 sessions per day (1 morning
and 1 afternoon) for 5 days with an electric current 2 mA;
- a group named G2 and treated by medication with escitalopram (Seroplex®) stabilized for
at least 1 month and sham tDCS.
These two groups are matched for age (+/- 5 years) and gender. The population of this study
will be comprised of patients over age 18 with unipolar depressive episode resistant episode
characterized by the failure of two antidepressant treatments for depressive episode and
treated by medication with escitalopram (Seroplex®) (20 mg/day), since at least 1 month. The
delay of one month is a minimum to observe a non-response. Moreover, in term of ethical
point of view, it's difficult to wait 6 to 8 weeks to observe the non-response to treatment.
These people will be recruited on a voluntary basis, after notification and consent in the
research center, the Psychiatry Clinical Department of the University Hospital of Besançon.
This study was conducted over a period of 15 months.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05324735 -
Pentoxifylline for Treatment of Resistant Major Depression
|
Phase 1/Phase 2 |